| RADOCHA, Jakub, Luděk POUR, Tomáš PIKA, Vladimír MAISNAR, Ivan ŠPIČKA, Evžen GREGORA, Marta KREJČÍ, Jiří MINAŘÍK, Kateřina MACHÁLKOVÁ, Jan STRAUB, Petr PAVLÍČEK, Roman HÁJEK a Pavel ŽÁK. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2016, roč. 96, č. 2, s. 119-127. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12556. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1318743,
author = {Radocha, Jakub and Pour, Luděk and Pika, Tomáš and Maisnar, Vladimír and Špička, Ivan and Gregora, Evžen and Krejčí, Marta and Minařík, Jiří and Machálková, Kateřina and Straub, Jan and Pavlíček, Petr and Hájek, Roman and Žák, Pavel},
article_location = {Hoboken},
article_number = {2},
doi = {http://dx.doi.org/10.1111/ejh.12556},
keywords = {multiple myeloma; free light chains; complete remission; overall survival; time to progression},
language = {eng},
issn = {0902-4441},
journal = {European Journal of Haematology},
title = {Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse},
volume = {96},
year = {2016}
}
TY - JOUR
ID - 1318743
AU - Radocha, Jakub - Pour, Luděk - Pika, Tomáš - Maisnar, Vladimír - Špička, Ivan - Gregora, Evžen - Krejčí, Marta - Minařík, Jiří - Machálková, Kateřina - Straub, Jan - Pavlíček, Petr - Hájek, Roman - Žák, Pavel
PY - 2016
TI - Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse
JF - European Journal of Haematology
VL - 96
IS - 2
SP - 119-127
EP - 119-127
PB - Wiley-Blackwell
SN - 09024441
KW - multiple myeloma
KW - free light chains
KW - complete remission
KW - overall survival
KW - time to progression
N2 - Introduction: The normalization of free light chain ratio (FLCr) has been introduced as a marker of stringent complete remission (CR) of multiple myeloma (MM). There is currently a lack of literature assessing the role of FLCr on MM disease progression and remission status. Patients and methods: A multicentered retrospective review of 125 patients with MM in CR and various FLCr values was completed. Parameters of interest included patient demographics, FLCr values, complete remission (CR)/relapse status, and time to progression (TTP). The FLCr values were recorded to provide time-dependent findings on the role of FLCr on progression-free survival and overall survival (OS). Results: The mean follow-up time of 125 patients from five hospitals in the Czech Republic was 31 months. A total of 47.2% of patients relapsed (54 of 125) during the follow-up period. The median TTP of patients with normal FLCr (n = 66) was 54.4 and 40.2 months for patients with abnormal FLCr (n = 59) (P = 0.217). None of the patients reached median overall survival regardless of FLCr values (P = 0.821). In the subgroup of newly diagnosed patients after upfront autologous stem cell transplantation (ASCT), there were 55.6% of patients (35 of 63) with normal FLCr and 44.4% (28 of 64) with abnormal FLCr. A total of 34.9% of patients (22 of 63) relapsed in this subgroup. Within the abnormal FLCr patients, a median TTP was 56.3 months, but no median TTP was reached among the normal FLCr patients (P = 0.746). Median OS in patients with normal (nFLCr) and abnormal FLCr (aFLCr) was not reached (P = 0.787). Conclusion: We did not observe any benefit from FLCr normalization in CR in myeloma patients in terms of progression-free survival or overall survival.
ER -
RADOCHA, Jakub, Luděk POUR, Tomáš PIKA, Vladimír MAISNAR, Ivan ŠPIČKA, Evžen GREGORA, Marta KREJČÍ, Jiří MINAŘÍK, Kateřina MACHÁLKOVÁ, Jan STRAUB, Petr PAVLÍČEK, Roman HÁJEK a Pavel ŽÁK. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2016, roč.~96, č.~2, s.~119-127. ISSN~0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12556.
|
